The White House has been detailing the Obama administration’s $215 million Precision Medicine initiative to enhance patient care via genomic research.
“Precision Medicine” seeks to use an individual’s genetic data, environment, and lifestyle characteristics to customize healthcare treatments and prevention strategies.
The bulk of the $215 million would go to the National Institutes of Health and the National Cancer Institute, with the Food and Drug Administration and the Office of the National Coordinator for Health Information Technology (ONC) receiving smaller amounts.
“Participants will be involved in the design of the initiative and will have the opportunity to contribute diverse sources of data — including medical records; profiles of the patient’s genes, metabolites (chemical makeup), and microorganisms in and on the body; environmental and lifestyle data; patient-generated information; and personal device and sensor data,” said the White House.
We at Cambridge Management Group would like to know more about how the president’s plan would affect research, and use of that research at hospitals, especially at teaching hospitals affiliated with medical schools engaged in intensive research. Hospital oncology departments would, presumably, be particularly big beneficiaries of the program.
Francis Collins, M.D., who runs the National Institutes of Health, has said the cancer part of the program is “much closer to clinical benefit” than many know.